Assessing the immunosuppressive activity of alginate-encapsulated mesenchymal stromal cells on splenocytes. Issue 1 (31st December 2022)

• Record Type: Journal Article
• Authors: Moise, Sandhya; Dolcetti, Luigi; Dazzi, Francesco; Roach, Paul; Buttery, Lee; MacNeil, Sheila; Medcalf, Nick
• Is Part Of: Artificial cells, nanomedicine, and biotechnology. Volume 50:Issue 1(2022)
• Page Start: 168
• Page End: 176
• Publication Date: 2022-12-31
• Subjects: Mesenchymal stromal cells -- immunosuppression -- alginate -- splenocytes -- encapsulation; Artificial cells -- Periodicals; Nanotechnology -- Periodicals; Blood substitutes -- Periodicals; Tissue engineering -- Periodicals; Molecules -- Periodicals; Biotechnology -- Periodicals; 615.39
• DOI: 10.1080/21691401.2022.2088547
• Languages: English
• ISSNs: 2169-1401

Abstract

Abstract: Mesenchymal stromal cells (MSCs) show immunosuppressive effects both via cell-to-cell contact (direct) with immune cells and by producing paracrine factors and extracellular vesicles (indirect). A key challenge in delivering this therapeutic effect in vivo is retaining the MSCs at the site of injection. One way to address this is by encapsulating the MSCs within suitable biomaterial scaffolds. Here, we assess the immunosuppressive effect of alginate-encapsulated murine MSCs on proliferating murine splenocytes. Our results show that MSCs are able to significantly suppress splenocyte proliferation by ∼50% via the indirect mechanism and almost completely (∼98%) via the direct mechanism. We also show for the first time that MSCs as monolayers on tissue culture plastic or encapsulated within alginate, when physically isolated from the splenocytes via transwells, are able to sustain immunosuppressive activity with repeated exposure to fresh splenocytes, for as long as 9 days. These results indicate the need to identify design strategies to simultaneously deliver both modes of MSC immunosuppression. By designing cell-biomaterial constructs with tailored degradation profiles, we can achieve a more sustained (avoiding MSCs migration and apoptosis) and controlled release of both the paracrine signals and eventually the cells themselves enabling efficient MSC-based immunosuppressive therapies for wound healing.